Improving Injectable Medicines Prescription in Outpatient

Services: A Path Towards Rational Use of Medicines in Iran by Bairami, Firoozeh et al.
Improving Injectable Medicines Prescription in Outpatient 
Services: A Path Towards Rational Use of Medicines in Iran
Firoozeh Bairami1, Fatemeh Soleymani2,3, Arash Rashidian1,4*
Abstract
Injection is one of the most common medical procedures in the health sector. Annually up to 16 billion injections are 
prescribed in low- and middle-income countries (LMICs), many of them are not necessary for the patients, increase 
the healthcare costs and may result in side effects. Currently over 40% of outpatient prescriptions in Iran contain at 
least one injectable medicine. To address the issue, a working group was established (August 2014 to April 2015) to 
provide a comprehensive policy brief to be used by national decision-makers. This report is the extract of methods 
that were followed and the main policy options for improving injectable medicines prescribing in outpatient services. 
Thirty-three potential policy options were developed focusing on different stakeholders. The panel reached consensus 
on seven policy options, noting effectiveness, cost, durability, and feasibility of each policy. The recommended policy 
options are targeted at patients and public (2 policies), insurers (2), physicians (1), pharmacies (1), and the Ministry 
of Health and Medical Education (MoHME) (1). 
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Statement of the Issue and Background 
Rational use of medicines is an important component of 
an effective health system.1 According to the World Health 
Organization’s (WHO’s) definition, rational use of medicines 
means “patients receive medications appropriate to their 
clinical needs, in doses that meet their own individual 
requirements, for an adequate period of time, and at the 
lowest cost to them and their community”2 but when the 
use of medicines is not compatible to the components of 
above-mentioned definition, the problem of irrational use of 
medicine does happen.3 Excessive use of antibiotics, overuse 
of injections rather than oral formulations, and not taking 
the full course of medications are among the most common 
types of inappropriate use of medicines.4 The magnitude of 
problem in overuse of injections and antibiotics is vast and 
worldwide and it is much more common in low- and middle-
income countries (LMICs).5
Injection is one of the most common medical procedures 
in the health sector. Annually up to 16 billion injections are 
prescribed in LMICs. In some setting, over 70% of injections 
are unnecessary or can be given in other formulations 
like oral medications.6 Injection is an invasive procedure 
which can lead to some side effects including bleeding, 
inflammation, atrophy, nerve injury, and in some cases 
hypersensitivity reactions such as anaphylactic shock.7 
Moreover, high rates of injection can increase the risks of 
spreading blood borne diseases such as hepatitis B, C, and 
HIV8 and incur unnecessary economic burden and costs on 
users and the health system.9,10 Injections should preferably 
be used in circumstances when safer delivery options (usually 
oral formulations) of medications are not available or if the 
patient is not to able to use oral formulations. This issue can 
be applied more stringently to outpatient settings where by 
definition patients need less injectable medicines.11
Current Situation
According to the WHO’s estimation the average rate of 
injections per person per year is about 3.4 in LMICs.12 A 
review in 1999 by the World Bank noted that 25%-96% of 
outpatient prescriptions in eight countries contained at 
least one injection.8 In another review that was conducted 
in 2000 based on 14 regional division defined by the global 
burden of disease project of the WHO, in the 10 regions 
(four predominantly affluent, developed regions excluded) 
the annual rate of injections per person ranged from 1.7 to 
11.3.13 More recent reports from countries confirm the high 
rate of injections. A study from Bangladesh reported more 
than 75% of patients received injection.14 This rate for Korea 
in 2004 was 30.9%.15 India and Cambodia reported 2.9 and 5.9 
injections per person per year, respectively.16,17 
Studies in Iran reveal that the rate of injections is high. This 
rate in a study conducted in 2009 was 58%18 and in another 
study the percentage was reported 41%.19
In 1997 to embed the concept of the rational use of medicines 
in health system body and to improve the standards of 
prescription issuance, the National Committee for Rational 
Use of Drug was established with 44 branches in medical 
universities across the country. Even though the committee 
and its subcommittees are working for more than 17 years, 
yet the rate of injections did not fall within the target range. 
According to the last report of committee, the rate of injection 
was estimated at 41%.20 To address the issue, a working group 
was established to provide a comprehensive policy brief. 
This report is the extract of methods that were followed and 
the main policy options for improving injectable medicines 
prescribing in outpatient services.
Options Extraction 
The policy brief reports the processes and results of a policy 
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development initiative to identify feasible interventions 
to reduce prescriptions including injectable medicines in 
outpatient services. The process involved targeted reviews of 
the literature, key informant consultations, open discussions 
within the working group, and a consensus development 
process using nominal group technique. 
Targeted Review of Literature
We searched the relevant literature to detect current scientific 
literature referring to the injectable medicines prescribing 
in outpatient services. The search was performed via online 
resources using the following research platforms: PubMed, 
Google Scholar, and Cochrane Library. We also reviewed 
pharmacology textbooks and WHO guidance21,22 for finding 
guidelines regarding injectable medicines prescribing in 
outpatient services.
Informant Consultations
In order to consider all factors leading to prescribe/use 
injectable medicines as much as possible, and also to consider 
unpublished reports, we interviewed five key informants. 
Four out of five had key positions in the health system and 
one had conducted an unpublished study regarding injection 
prescribing practices in the country.
Open Discussions Within the Working Group
To finalize the leading factors and to provide policy options 
the working group held open discussion sessions with 
all stakeholders attending the meeting. The participants 
suggested policy options according to their background.
Consensus Development
Accordingly, policy options were provided for each factor. 
Then in next step, the working group followed a nominal 
group technique approach to reach consensus on policy 
options based on four dimensions including effect, cost, 
durability, and feasibility of different options. In the final 
step, percentages of each item were calculated and results 
categorized in 3 domains: low, medium, and high support. 
Each intervention (policy option) that received the highest 
votes of support was taken into account for implementation. 
The working group also discussed different interventional 
approaches for changing professional behavior.23,24 
Working Group Member and Setting 
The working group comprised of 10 key experts representing 
important stakeholders, including Food and Drug 
Organization, Health Insurance Organizations, Medical 
Council Organization relevant academics, researchers, and 
representatives of pharmacists. 
Results
The working group identified 33 policy options considering 
four dimensions including effect, cost, durability, and feasibility 
of each option (Additional file 1) the dimensions were 
extracted from a previous extensive work on categorization of 
intervention to change professional behavior.23 After scoring 
to each item, seven policy options selected for implementing. 
The results were summarized in Table. We used the format of 
a published policy brief for shaping and reporting our final 
options.25
Discussion
The high rate of prescribed injections as one of the most 
considerable problems is now on our health policy-makers’ 
agenda. Even though the magnitude of the problem is known, 
Table. Policy Options
Policy Options Policy Description Advantages/Disadvantages
1. Developing evidence-based clinical 
guidelines containing recommendations for 
appropriate prescribing
This policy option targets doctors and is designed 
in response to a perceived lack of knowledge about 
effective alternative methods for patient management.
This Policy has a low implementing cost – is 
expected to have a modest effect for a reasonable 
period of time. Its feasibility is acceptable.
2. Enforcing the regulations for dispensing of 
non-prescription medicines
In response to providing injectable medicines without 
prescription. It is aimed at pharmacies. 
The cost of implementing this policy is low with a 
good effect in reasonable period of time. However, 
the feasibility of implementing it is low.
3. Using mass media to increase public 
awareness regarding side effects of injection
Public may demand injectable medicines. Using mass 
media can Increase awareness of a large number of 
people.
We expect a small effect from this policy, effective 
use of mass media might be costly. The durability 
and feasibility of implementing is reasonable.
4. Interventions to change public attitude 
toward reducing injectable medicines 
demand
Because of lack of knowledge people think injecteble 
medicines are more effective than other form of 
medicines. In this regard, increasing knowledge is useful 
which is possible with changing public attitude.
We can implement this policy easily with a low cost 
but as the target group is the whole society and the 
policy is not personalized the effect is low and will 
decrease during time.
5. Increasing coordination between the 
insurer and MoHME monitoring activities
Insurance organizations can play an effective role in 
managing prescribing injectable medicines and this 
would be possible with the leverage of monitoring 
activities. 
Even though the cost of implementing this policy 
is high but the effect is very good and can last for a 
long time and it can be easily implemented.
6. Changing the policy of auditing the 
number of medicinal items in each 
prescription to the content of prescriptions 
(interactions, effectiveness, relevance)
Insurers can check the content of a prescription to 
watch which form of medicines have been prescribed 
rather than to check the number of medicinal items (The 
current policy is to count the number of medicines).
Implementing this policy can be considered as a 
rational choice because with a reasonable cost we 
will have a very good effect in a long period of time.
7. Developing clear guidance for use of 
injectable medicines in outpatient settings 
MoHME as the main policy-maker in the country can 
control the issue by developing proper guidelines 
regarding injection.
This policy can be implemented easily by a 
reasonable cost. However, its effect is low and it 
can last for a long period of time.
Abbreviation: MoHME, Ministry of Health and Medical Education.
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there is a big gap in literature regarding the effectiveness 
of interventions that can be used to reduce prescriptions 
containing injectable medicines. We could not find any 
explicit criteria in pharmacology textbook21 regarding the 
standard number of prescribing injections or the condition 
that we should prescribe injections particularly in outpatient 
services, although WHO’s handbook for good prescription has 
recommended that less 10% of outpatient prescriptions should 
contain injectable medicines.22 We identified 13 stakeholders 
(Figure) which seven of them were considered as the main 
stakeholders and the others as the secondary stakeholders. 
The interventions were targeted at these stakeholders to guide 
implementation processes. 
The panel reached consensus on seven policy options, noting 
effectiveness, cost, durability, and feasibility of each policy. To 
categorize the interventions, we used a previously developed 
conceptual framework23 which classifies the interventions 
to two types including voluntary and non-voluntary 
(obligatory) interventions. Voluntary interventions include 
the interventions that target providers’ internal or external 
motivations. Such categorization helps to define the policies 
so that both the personal attributes and environmental factors 
are considered when the interventions are designed and 
implemented. 
We also suggested intervention by targeting stakeholders in 
this process. The majority of previous studies which have 
been conducted regarding injections, mainly have considered 
issues associated to patients such as their beliefs in order to 
faster and better effect of injection in comparison to oral 
formulations, lack of awareness regarding the side effects of 
injections, and socio-cultural factors7,11,26,27 that cause patients 
asks their doctors to prescribe injectable medicines. The other 
studies considerably highlight some factors related to doctors, 
including economic and financial reasons, competition and 
pressure from third parties (pharmacies, injection units, and 
patients)7,14,28,29 that have been taking into account as the main 
factors drive them to prescribe injectable medicines regardless 
of actual indications.
le Grand and colleagues define another classification of 
interventions in this regard which includes educational, 
managerial, and financial policy options.30 According to the 
literature review, researchers mostly focus on educational 
options5,26 and their effectiveness in reducing use of 
injections.31 Educational options refer to train people via 
mass media, schools or group discussion, continuous medical 
education for doctors and developing related educational 
curriculum in schools of pharmacy and medicine. Interactive 
group discussions can be more effective educational strategies 
to decrease the rate of unnecessary injections.31,32 Briefly, 
empowering people and changing their beliefs and norms 
regarding overuse of injections may sound time taking 
process but it can be useful.4
But there are other leverages that we have considered as policy 
option in the category of managerial, like monitoring (doctors, 
pharmacies, and injection units), restricting pharmaceutical 
list, developing guidelines, restricting delivery of over the 
counter medicines and revision of existing interventions. 
Financial interventions include provision of insurance 
coverage of injectable medicines (which will enable regulatory 
oversight of their use by insurance organizations), removing 
doctor-patient financial relation by capitation payment and 
elimination of financial incentives in provision of injection 
services by doctors.33
The priority of implementation of policy options preferably is 
like managerial and educational, respectively.30,31 This is what 
our report shows too.
The financial policy options were not in favorable position 
to be implemented. It seems the same is applicable in other 
settings.30,34
The main limitation of our study was the lack of previous 
studies regarding appropriate interventions in this field. 
There are a lot of studies regarding injection safety but we 
rarely could find studies about the interventions to reduce 
injections rate.
Conclusion
Reducing use of injectable medicines in outpatient settings 
is affected by different factors and stakeholders. Effective 
reduction in such inappropriate usage of medicines needs 
persistency in policy-making and implementation and clear 
Figure. Main Stakeholders of Prescribing and Using Injectable Medicines in Outpatient Services. FDO, Food and Drug Organization.
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attention in legitimate concerns of the different stakeholders.
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